On Monday, the top US health agency granted full approval to Pfizer-BioNTech’s two-shot messenger RNA (mRNA) Covid-19 vaccine, making it the first for the United States. Janet Woodcock, the acting head of the Food and Drug Administration (FDA), called the approval a ‘milestone’.

While, the other vaccines have met the Food and Drug Administration rigorous, scientific standards for emergency uses authorisation (EUA) and first FDA-approved in Covid-19 vaccine, the public can be very confident that vaccine meets for the high standards for safety, effectiveness or  manufacturing quality the agency requires of an approved product.

The full authorisation will address reservations harboured by people who refused to be vaccinated citing EUA granted to all Covid-19 vaccines available in the United States thus far. It will allow the company to retail the vaccine more freely, through pharmacies and also advertise it. The EUA approval for Moderna’s two-shot vaccine, they have also based on mRNA technology followed shortly and then Johnson & Johnson’s one-shot vaccine. AstraZeneca’s vaccine, which is used in India as Covishield has still not been authorized for use, not even emergency one.

Pfizer-BioNTech s Covid-19 vaccine was the first to be used in the United States after the FDA granted it EUA in 2020 December 11, for people 16 years of age and older. Its rollout was a national event, reported breathlessly from the first truck that left the company’s plant in Portage, on December 13 Michigan, to the administering of the first shot to a healthcare worker at a New York hospital on December 14.